Novavax Shares Edge Down 0.6% After Nuvaxovid Gets XFG Approval in Three Markets
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Novavax Shares Edge Down 0.6% After Nuvaxovid Gets XFG Approval in Three Markets
GAITHERSBURG, Maryland, August 28, 2026, 12:16 (EDT) Novavax stock was at $9.00, falling 0.6% following the update on three-market approval.Sanofi's sales may produce royalties ranging from the high teens up to the low twenties percent.Novavax's 2026 revenue outlook does not include those royalties and milestones connected to Sanofi. Novavax, Inc. (NASDAQ: NVAX) announced that its…
Novavax partners secure Nuvaxovid approvals for 2026-2027 season
GAITHERSBURG, Md. — Novavax said its partners have received regulatory approvals for an updated formulation of Nuvaxovid targeting the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in the United States, the European Union and Japan.The approvals position the protein-based, non-mRNA COVID-19 vaccine for use in the upcoming vaccination season and allow Novavax to continue earning royalties on sales by its commercial partners.Sanofi l…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
